Ferroptosis and PPAR-gamma in the limelight of brain tumors and edema.
SLC7A11
ferroptosis
glioblastoma
glutamate
peritumoral edema
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
02
2023
accepted:
04
07
2023
medline:
9
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Human malignant brain tumors such as gliomas are devastating due to the induction of cerebral edema and neurodegeneration. A major contributor to glioma-induced neurodegeneration has been identified as glutamate. Glutamate promotes cell growth and proliferation in variety of tumor types. Intriguently, glutamate is also an excitatory neurotransmitter and evokes neuronal cell death at high concentrations. Even though glutamate signaling at the receptor and its downstream effectors has been extensively investigated at the molecular level, there has been little insight into how glutamate enters the tumor microenvironment and impacts on metabolic equilibration until recently. Surprisingly, the 12 transmembrane spanning tranporter xCT (SLC7A11) appeared to be a major player in this process, mediating glutamate secretion and ferroptosis. Also, PPARγ is associated with ferroptosis in neurodegeneration, thereby destroying neurons and causing brain swelling. Although these data are intriguing, tumor-associated edema has so far been quoted as of vasogenic origin. Hence, glutamate and PPARγ biology in the process of glioma-induced brain swelling is conceptually challenging. By inhibiting xCT transporter or AMPA receptors in vivo, brain swelling and peritumoral alterations can be mitigated. This review sheds light on the role of glutamate in brain tumors presenting the conceptual challenge that xCT disruption causes ferroptosis activation in malignant brain tumors. Thus, interfering with glutamate takes center stage in forming the basis of a metabolic equilibration approach.
Identifiants
pubmed: 37554158
doi: 10.3389/fonc.2023.1176038
pmc: PMC10406130
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1176038Informations de copyright
Copyright © 2023 Yakubov, Schmid, Hammer, Chen, Dahlmanns, Mitrovic, Zurabashvili, Savaskan, Steiner and Dahlmanns.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Antioxidants (Basel). 2023 Feb 01;12(2):
pubmed: 36829908
Cell Mol Life Sci. 2014 May;71(10):1839-54
pubmed: 24281762
Expert Opin Drug Saf. 2016;15(4):457-65
pubmed: 26789102
Front Oncol. 2021 Dec 01;11:783067
pubmed: 34926298
Nat Med. 2013 May;19(5):557-66
pubmed: 23652116
Neurocrit Care. 2020 Jun;32(3):647-666
pubmed: 32227294
Cancer Biol Ther. 2015;16(8):1205-13
pubmed: 26047211
Nat Med. 1998 Sep;4(9):1046-52
pubmed: 9734398
Curr Opin Oncol. 2004 Nov;16(6):593-600
pubmed: 15627023
Neurochem Int. 2000 Aug-Sep;37(2-3):317-29
pubmed: 10812217
Brain Res. 2006 Aug 2;1102(1):175-8
pubmed: 16806109
Int J Cancer. 2018 Mar 15;142(6):1266-1276
pubmed: 29067692
Exp Neurol. 2022 Aug;354:114100
pubmed: 35490721
Glia. 2000 Oct;32(1):1-14
pubmed: 10975906
Nat Chem Biol. 2017 Jan;13(1):91-98
pubmed: 27842070
Front Neurosci. 2021 May 28;15:666679
pubmed: 34121995
J Pediatr. 2005 May;146(5):688-92
pubmed: 15870676
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Drug Dev Res. 2019 Sep;80(6):758-777
pubmed: 31199023
Neurochem Int. 2007 Nov-Dec;51(6-7):333-55
pubmed: 17517448
Trends Cancer. 2020 Mar;6(3):223-235
pubmed: 32101725
Proc Natl Acad Sci U S A. 2023 Apr 18;120(16):e2222084120
pubmed: 37040416
Sci Rep. 2014 Sep 17;4:6226
pubmed: 25228443
Oncotarget. 2016 Jun 14;7(24):36021-36033
pubmed: 27074570
N Engl J Med. 2001 Jan 11;344(2):114-23
pubmed: 11150363
J Neurosci. 2005 Aug 3;25(31):7101-10
pubmed: 16079392
Brain Res. 1992 Feb 28;573(2):324-6
pubmed: 1354550
J Cancer. 2021 Feb 5;12(7):2073-2082
pubmed: 33754006
Front Pharmacol. 2022 Jul 22;13:921070
pubmed: 35935861
Adv Neurol. 1980;28:345-58
pubmed: 7457251
Clin Immunol. 2023 Jun;251:109333
pubmed: 37088298
CNS Neurosci Ther. 2021 Jan;27(1):134-144
pubmed: 33421349
J Cereb Blood Flow Metab. 2016 Mar;36(3):513-38
pubmed: 26661240
Int J Oncol. 2004 Aug;25(2):493-502
pubmed: 15254749
Front Oncol. 2018 Sep 04;8:331
pubmed: 30234009
J Intensive Care Med. 2017 Jan;32(1):15-24
pubmed: 26647408
Cancer Cell. 2015 Oct 12;28(4):441-455
pubmed: 26461092
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
Acta Neurochir Suppl. 2003;86:305-7
pubmed: 14753458
Oncotarget. 2017 May 9;8(19):32345-32355
pubmed: 28423683
Glia. 2004 Jan 15;45(2):133-43
pubmed: 14730707
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6
pubmed: 22323597
J Neurochem. 2014 Mar;128(5):617-27
pubmed: 24164438
Nature. 2017 Nov 9;551(7679):247-250
pubmed: 29088702
Childs Nerv Syst. 2016 Dec;32(12):2293-2302
pubmed: 27613642
Neurosurg Focus. 2007 May 15;22(5):E8
pubmed: 17613239
Free Radic Biol Med. 2019 Apr;134:445-457
pubmed: 30731113
Neurotherapeutics. 2019 Oct;16(4):1133-1148
pubmed: 31512062
PLoS One. 2009 Nov 13;4(11):e7752
pubmed: 19915670
Curr Issues Mol Biol. 2022 Dec 19;44(12):6439-6449
pubmed: 36547100
Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H659-H668
pubmed: 29127238
Breast Cancer Res Treat. 2002 Jul;74(2):155-65
pubmed: 12186376
Brain Res. 2015 Oct 22;1624:199-207
pubmed: 26220473
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Pflugers Arch. 2010 Jul;460(2):525-42
pubmed: 20229265
J Neurosci Res. 1998 May 1;52(3):307-21
pubmed: 9590439
Nat Biomed Eng. 2019 Mar;3(3):230-245
pubmed: 30948807
J Neurooncol. 1991 Apr;10(2):179-85
pubmed: 1654403
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E4966-75
pubmed: 27506793
Cancer Chemother Pharmacol. 2013 Apr;71(4):929-36
pubmed: 23358645
Curr Neuropharmacol. 2015;13(2):258-65
pubmed: 26411769
Cell Death Differ. 2016 Mar;23(3):369-79
pubmed: 26794443
Biochem Biophys Res Commun. 2021 Oct 22;576:33-39
pubmed: 34478917
Front Pharmacol. 2022 Apr 20;13:869300
pubmed: 35517804
Front Mol Neurosci. 2019 Mar 29;12:65
pubmed: 30983966
Expert Opin Ther Targets. 2009 Jun;13(6):719-31
pubmed: 19456273
Oncogene. 2016 Dec 1;35(48):6246-6261
pubmed: 27157615
Biol Trace Elem Res. 2014 Dec;161(3):246-54
pubmed: 25164034
Oncotarget. 2016 Nov 15;7(46):74630-74647
pubmed: 27612422
Cancer Sci. 2009 Oct;100(10):1856-62
pubmed: 19681905
Sci Adv. 2022 Feb 4;8(5):eabl8920
pubmed: 35108055
Antioxidants (Basel). 2021 Dec 14;10(12):
pubmed: 34943091
Cancer Res. 1999 Sep 1;59(17):4383-91
pubmed: 10485487
Oncotarget. 2015 Aug 28;6(25):21301-14
pubmed: 26046374
Case Rep Med. 2020 Jan 28;2020:7981609
pubmed: 32082381
J Mol Med (Berl). 2009 Feb;87(2):153-67
pubmed: 19066835
Science. 1990 Feb 2;247(4942):571-4
pubmed: 2154034
J Biol Chem. 2009 Nov 6;284(45):30836-44
pubmed: 19744930
Ann Oncol. 2021 Feb;32(2):171-182
pubmed: 33246022
J Clin Neurosci. 2015 Jan;22(1):21-8
pubmed: 25439749
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
Mol Cell Biochem. 2016 Jul;418(1-2):167-78
pubmed: 27334753
Front Oncol. 2015 Jul 06;5:153
pubmed: 26217588
Discov Oncol. 2022 Sep 28;13(1):94
pubmed: 36169772
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
Nat Commun. 2022 Feb 17;13(1):925
pubmed: 35177622
Front Oncol. 2022 Apr 21;12:861834
pubmed: 35530363
Brain Sci. 2022 Jun 19;12(6):
pubmed: 35741689
Continuum (Minneap Minn). 2021 Oct 1;27(5):1172-1200
pubmed: 34618757
Curr Neuropharmacol. 2016;14(1):48-54
pubmed: 26521944
Neural Regen Res. 2016 Nov;11(11):1752-1753
pubmed: 28123410
Thromb Haemost. 2009 Jun;101(6):999-1005
pubmed: 19492139
Nature. 2017 Jul 27;547(7664):453-457
pubmed: 28678785
N Engl J Med. 1975 Oct 2;293(14):706-11
pubmed: 1160939
Front Biosci (Landmark Ed). 2023 Mar 20;28(3):57
pubmed: 37005761
PPAR Res. 2008;2008:204514
pubmed: 18725982
Biochem Biophys Res Commun. 2012 Jan 6;417(1):552-7
pubmed: 22177955
Stroke. 2005 Mar;36(3):654-9
pubmed: 15692110
Front Oncol. 2022 Feb 23;12:858462
pubmed: 35280777
Int J Mol Sci. 2021 Dec 13;22(24):
pubmed: 34948178
J Cancer Res Ther. 2019;15(4):927-932
pubmed: 31436254
Cell. 2015 May 7;161(4):803-16
pubmed: 25913192
Oncotarget. 2017 May 9;8(31):51164-51176
pubmed: 28881638
Cell Mol Neurobiol. 2021 Mar;41(2):263-278
pubmed: 32314126
PLoS One. 2014 Apr 08;9(4):e93264
pubmed: 24714627
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
PPAR Res. 2010;2010:785369
pubmed: 20069049
Nat Med. 2008 Jun;14(6):629-32
pubmed: 18469825
J Neurooncol. 2010 Nov;100(2):233-9
pubmed: 20443132
J Neurosci Res. 2001 Dec 1;66(5):967-71
pubmed: 11746425
J Biol Chem. 2001 Jul 6;276(27):24667-73
pubmed: 11319222
Bioengineered. 2022 Apr;13(4):10540-10551
pubmed: 35441580
Int J Mol Sci. 2016 Dec 28;18(1):
pubmed: 28036023
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Annu Rev Pharmacol Toxicol. 1999;39:431-56
pubmed: 10331091
Ann Anat. 2010 Sep 20;192(5):309-13
pubmed: 20801625
Mol Neurobiol. 2015;51(3):966-79
pubmed: 24865512
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945
Oncogene. 2017 Oct 5;36(40):5593-5608
pubmed: 28553953
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24
pubmed: 8281615
Neuroscience. 2004;129(4):1011-20
pubmed: 15561416
Int J Cancer. 2004 Nov 1;112(2):231-8
pubmed: 15352035